Paper Details

  1. Home
  2. Paper Details

Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial.

Author: BoiardiLuigi, CantiniFabrizio, CatanosoMaria Grazia, CimminoMarco, GerliRoberto, HunderGene G, KlersyCatherine, MacchioniPierLuigi, ManganelliPaolo, ManziniCarlo, PaolazziGiuseppe, SalvaraniCarlo, TrottaAldo

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Adding infliximab to prednisone for treating newly diagnosed polymyalgia rheumatica did not improve the outcome compared to placebo.
Paper Details　
Original Abstract of the Article :
BACKGROUND: A reliable alternative to steroids for treating polymyalgia rheumatica has not yet been identified. Although infliximab has been used occasionally in steroid-resistant cases, its efficacy has not been demonstrated in a controlled study. OBJECTIVE: To compare the efficacy of prednisone p...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.7326/0003-4819-146-9-200705010-00005

データ提供：米国国立医学図書館（NLM）

Infliximab for Polymyalgia Rheumatica: A Randomized Trial

Polymyalgia rheumatica (PMR) is a common inflammatory condition that often requires corticosteroid treatment. This randomized, placebo-controlled trial investigated the efficacy of infliximab, a tumor necrosis factor (TNF) inhibitor, in combination with prednisone for the initial treatment of PMR. The results indicated that infliximab did not provide additional benefit compared to placebo in this setting. The authors suggest that further research is needed to evaluate the potential role of TNF inhibitors in the management of PMR.

Exploring New Avenues for PMR Treatment

The trial's findings suggest that infliximab, a commonly used TNF inhibitor, may not be effective in treating PMR. While this study provides valuable information, further research is needed to explore the potential role of other TNF inhibitors or alternative therapeutic approaches in the management of PMR. The quest for effective treatments for PMR continues, as researchers strive to find new and innovative approaches to alleviate this debilitating condition.

Navigating the Complexities of PMR Management

This trial underscores the complexities of managing PMR. While corticosteroids remain the mainstay of treatment, ongoing research is crucial to explore alternative therapies that can effectively manage this condition. It is important to consult with a rheumatologist to discuss individualized treatment options based on specific needs and clinical factors. The search for optimal PMR treatments continues, with researchers dedicated to finding better solutions for patients.

Dr.Camel's Conclusion

This randomized trial provides valuable insights into the potential role of infliximab in the initial treatment of polymyalgia rheumatica. The study's findings indicate that infliximab does not offer additional benefit compared to placebo, suggesting that further research is needed to explore other therapeutic options for this condition. The pursuit of effective PMR treatments continues, with researchers dedicated to finding new and innovative approaches to alleviating this debilitating condition.

Date :
  1. Date Completed 2007-05-14
  2. Date Revised 2022-03-31
Further Info :

Pubmed ID

17470831

DOI: Digital Object Identifier

10.7326/0003-4819-146-9-200705010-00005

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.